SJS Investment Consulting’s Beam Therapeutics BEAM Stock Holding History

SJS Investment Consulting’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$318	Sell	13 -22	-63%	-$612	﹤0.01%	2845
2026 Q2	$1.2K	Buy	35 +32	+1,067%	+$966	﹤0.01%	1963
2026 Q1	$72	Hold	3	–	–	﹤0.01%	2190
2025 Q4	$84	Buy	+3	New	+$77	﹤0.01%	1964
2025 Q2	–	Sell	-5	Closed	-$98	–	1567
2025 Q1	$98	Hold	5	–	–	﹤0.01%	1523
2024 Q4	$124	Buy	5 +3	+150%	+$77	﹤0.01%	1507
2024 Q3	$49	Hold	2	–	–	﹤0.01%	1621
2024 Q2	$47	Buy	+2	New	+$49	﹤0.01%	1623

Other funds holding BEAM

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

ARK Investment Management St. Petersburg, Florida $17.4B AUM 41.01% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Nikko Asset Management Americas New York $8.04B AUM 33.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

SJS Investment Consulting's BEAM Position: Q3 2026 in Review

SJS Investment Consulting reduced its Beam Therapeutics (BEAM) stake by 63% in Q3 2026, selling an estimated $612 and leaving 13 shares worth $318. The position accounts for ﹤0.01% of the portfolio, ranked #2845.

SJS Investment Consulting first reported a position in BEAM in Q2 2024 and has held it in 8 quarters since. The position peaked at $1.2K in Q2 2026. 191 funds tracked by Wall St. Rank hold BEAM as of Q3 2026.

SJS Investment Consulting held 13 shares of Beam Therapeutics worth $318 as of Q3 2026.
SJS Investment Consulting sold 22 Beam Therapeutics shares in Q3 2026, an estimated $612.
Beam Therapeutics made up ﹤0.01% of SJS Investment Consulting's portfolio in Q3 2026, its #2845 holding.
SJS Investment Consulting first reported a position in Beam Therapeutics in Q2 2024 and has held it in 8 quarters since.
SJS Investment Consulting's Beam Therapeutics position peaked at $1.2K in Q2 2026.
191 funds tracked by Wall St. Rank held Beam Therapeutics as of Q3 2026.

Based on SJS Investment Consulting's 13F filing for Q3 2026, filed 26 Oct 2026.